395 related articles for article (PubMed ID: 30657975)
1. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
3. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.
Espinel-Ingroff A; Chowdhary A; Cuenca-Estrella M; Fothergill A; Fuller J; Hagen F; Govender N; Guarro J; Johnson E; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; Trilles L; Kidd S; Turnidge J
Antimicrob Agents Chemother; 2012 Jun; 56(6):3107-13. PubMed ID: 22391546
[TBL] [Abstract][Full Text] [Related]
4. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
Chong HS; Dagg R; Malik R; Chen S; Carter D
J Clin Microbiol; 2010 Nov; 48(11):4115-20. PubMed ID: 20844209
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.
Andrade-Silva L; Ferreira-Paim K; Mora DJ; Da Silva PR; Andrade AA; Araujo NE; Pedrosa AL; Silva-Vergara ML
Med Mycol; 2013 Aug; 51(6):635-40. PubMed ID: 23343452
[TBL] [Abstract][Full Text] [Related]
7. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
Carvajal SK; Melendres J; Escandón P; Firacative C
Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
[TBL] [Abstract][Full Text] [Related]
8. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.
Matos CS; de Souza Andrade A; Oliveira NS; Barros TF
Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1647-52. PubMed ID: 22278291
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of the Vitek 2 antifungal susceptibility system and E-test with the CLSI M27-A3 broth microdilution method for susceptibility testing of Indian clinical isolates of Cryptococcus neoformans.
Tewari A; Behera B; Mathur P; Xess I
Mycopathologia; 2012 Jun; 173(5-6):427-33. PubMed ID: 22354778
[TBL] [Abstract][Full Text] [Related]
10. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains.
Silva DC; Martins MA; Szeszs MW; Bonfietti LX; Matos D; Melhem MS
Diagn Microbiol Infect Dis; 2012 Apr; 72(4):332-9. PubMed ID: 22341512
[TBL] [Abstract][Full Text] [Related]
12. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.
Trilles L; Meyer W; Wanke B; Guarro J; Lazéra M
Med Mycol; 2012 Apr; 50(3):328-32. PubMed ID: 21859388
[TBL] [Abstract][Full Text] [Related]
13. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
15. Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry.
Morales BP; Junior IN; Trilles L; Bertho AL; Oliveira Rde V; Nishikawa MM; Elias Mdos S; Wanke B; Lazéra Mdos S
Med Mycol; 2014 Jan; 52(1):90-8. PubMed ID: 23808405
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates.
Dias ALT; Matsumoto FE; Melhem MSC; da Silva EG; Auler ME; de Siqueira AM; Paula CR
J Med Microbiol; 2006 Dec; 55(Pt 12):1693-1699. PubMed ID: 17108273
[TBL] [Abstract][Full Text] [Related]
17. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of Cryptococcus gattii clinical isolates.
Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
20. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.
Souza LK; Souza Junior AH; Costa CR; Faganello J; Vainstein MH; Chagas AL; Souza AC; Silva MR
Mycoses; 2010 Jan; 53(1):62-7. PubMed ID: 19500261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
